Fisetin ameliorates polycystic ovary syndrome in rats via a mechanistic modulation of AMP-activated protein kinase and SIRT1 molecular pathway
Naunyn-Schmiedeberg's Archives of Pharmacology · 2024-12 · 397 (12) · 10017-10029
DOI: 10.1007/s00210-024-03257-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 04.07.2024. Verfasst von Simerjeet Kaur Chahal und 1 weiteren Autor:innen. Beteiligte Einrichtung: University Institute of Pharma Sciences, Chandigarh University, Gharuan, Mohali, 140413, Punjab, India. Hauptthemen laut MEDLINE: Polycystic Ovary Syndrome, Flavonols, Rats, Sprague-Dawley, AMP-Activated Protein Kinases. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 53 Literaturangaben.
Abstract (Originalsprache)
Fisetin, a polyphenolic flavonoid, exhibits numerous pharmacological activities against metabolic syndromes. The present research aims to explore the therapeutic efficacy of fisetin in experimental polycystic ovary syndrome (PCOS). Female Sprague-Dawley rats were administered mifepristone (20 mg/kg/day) to induce PCOS. PCOS rats were treated with fisetin (20 mg/kg and 40 mg/kg) and further compared with metformin HCl, the conventional drug for PCOS. The mechanism of fisetin was explored using dorsomorphin (an AMPK inhibitor). Then, rats were sacrificed for further analysis of biochemical and histological parameters. PCOS rats exhibited irregular estrous cycles, increased serum testosterone (4.72 ± 0.139 ng/ml), estradiol (750.2 ± 16.56 pg/ml), LH (30.33 ± 1.563 mIU/ml), HOMA-IR (1.115 ± 0.049), TNF-α (86.59 ± 3.93 pg/ml), IL-6 (55.34 ± 4.432 pg/ml), and TBARS (3.867 ± 0.193 µmol/mg) along with declined progesterone (11.67 ± 1.54 ng/ml), FSH (13.33 ± 1.256 mIU/ml), GSH (33.47 ± 1.348 µmol/mg) levels, and SOD (2.163 ± 0.298 U/mg) activity as compared to normal control group. Fisetin high dose significantly lowers testosterone (3.014 ± 0.234 ng/ml), estradiol (533.7 ± 15.39 pg/ml), LH (16.67 ± 1.62 mIU/ml), HOMA-IR (0.339 ± 0.20), TNF-α (46.02 ± 2.66 pg/ml), IL-6 (31.77 ± 3.47 pg/ml), and TBARS (1.747 ± 0.185 µmol/mg) and enhances progesterone (33.17 ± 1.447 ng/ml), FSH (27.17 ± 1.42 mIU/ml), GSH (60.35 ± 1.1.102 µmol/mg) levels, and SOD (4.513 ± 0.607 U/mg) activity. The histology of ovarian tissues shows a significant increase in cystic follicles in PCOS rats compared with the normal control group. These alterations were attenuated with fisetin treatment. Administration of dorsomorphin with fisetin can reverse the beneficial effects of fisetin in PCOS rats. Altogether, these present findings highlight the potential of fisetin as a promising therapeutic intervention for the management of PCOS by modulating AMPK/SIRT1 signaling in rats.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University Institute of Pharma Sciences, Chandigarh University, Gharuan, Mohali, 140413, Punjab, India.
- University Institute of Pharma Sciences, Chandigarh University, Gharuan, Mohali, 140413, Punjab, India. atul.kbr@gmail.com.
Zitieren
APA
Chahal, S. K., & Kabra, A. (2024). Fisetin ameliorates polycystic ovary syndrome in rats via a mechanistic modulation of AMP-activated protein kinase and SIRT1 molecular pathway. Naunyn-Schmiedeberg's Archives of Pharmacology, 397(12), 10017-10029. https://doi.org/10.1007/s00210-024-03257-7
Vancouver
Chahal SK, Kabra A. Fisetin ameliorates polycystic ovary syndrome in rats via a mechanistic modulation of AMP-activated protein kinase and SIRT1 molecular pathway. Naunyn-Schmiedeberg's Archives of Pharmacology. 2024;397(12):10017-10029. doi:10.1007/s00210-024-03257-7
BibTeX
@article{Chahal2024,
author = {Chahal, Simerjeet Kaur and Kabra, Atul},
title = {Fisetin ameliorates polycystic ovary syndrome in rats via a mechanistic modulation of AMP-activated protein kinase and SIRT1 molecular pathway},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2024},
volume = {397},
number = {12},
pages = {10017--10029},
doi = {10.1007/s00210-024-03257-7}
}
EUVIMED